Zacks Investment Research
03 Jun 2026, 18:45 UTC · 2h ago
Here's Why You Should Add PacBio Stock to Your Portfolio Now
Search tags
Zacks Investment Research
03 Jun 2026, 18:45 UTC · 2h ago
Search tags
Story key points
4 claims · impact-rated
Pacific Biosciences (PACB) projects 22.6% growth for 2026. — Strong forward-looking growth guidance is a primary driver for valuation and investor confidence.
+0.60PacBio has beaten Zacks Consensus earnings estimates in all four of its most recent quarters with an average surprise of 29.8%. — Consistent earnings beats demonstrate operational strength and a tendency for the company to outperform market expectations.
+0.40PacBio's SPRQ-Nx chemistry is enabling human whole-genome sequencing costs to drop below $300 at scale. — Significant cost reductions in core products typically expand the addressable market and increase competitive advantage.
+0.30The company continues to face concerns regarding funding headwinds. — Liquidity or funding risks can offset growth optimism and create volatility in small-cap biotech stocks.
Continue reading
6 related stories
Ticker attribution
Model heads
The company has a Zacks Rank #2 (Buy), strong first-quarter results, and consistent earnings surprises, despite some funding headwinds.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
